Neuromyelitis Optica

Neuromyelitis Optica Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 [Upcoming Report]

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages

  • View Count

Example Insights

  • The global Neuromyelitis optica market is primarily being driven by the rising incidence of the disease, growing pipeline of drugs for treatment of Neuromyelitis optica and regulatory approvals of drugs whereas unavailability of disease-specific treatment has been observed as a major roadblock for Neuromyelitis optica market. 
  • Owing to the rise in R&D activity and increasing interest of stakeholders to invest in this field, the market is anticipated to grow at a significant pace in the coming years.
  • Factors such as rise in awareness of disease, development of early diagnosis methods and development of solutions for long-term suppression of the disease are likely to influence the overall market in the coming years. 
  • More novel therapy solutions are being developed by various industry as well as non-industry stakeholders, which are actively focused on addressing the challenges related to relapse symptoms of Neuromyelitis optica.
  • The significant impact on market size can also be attributed to the contributions of several big pharma players, such as Alexion Pharmaceuticals, AstraZeneca, Genentech and Roche, being actively involved in evaluation of various therapy candidates in this field. 
  • With various potential therapies under clinical investigation, a marked rise is anticipated in the number of new entrants in the market, in the coming years. 

Report Description

Neuromyelitis Optica Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 report by Roots Analysis outlays comprehensive insights about the current market landscape, offering an informed opinion on the likely adoption of Neuromyelitis optica therapeutics, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. 

This report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Neuromyelitis optica. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the drug’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies developed / being developed for treatment of Neuromyelitis optica, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030.

Scope of the Report

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development, type of molecule, type of therapy, mechanism of action, dosing frequency and route of administration of the drugs / therapies being developed for the treatment of Neuromyelitis optica. 
  • Detailed profiles of the players that are engaged in the development of drug products / therapies for Neuromyelitis optica, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
  • An analysis of the partnerships that have been established between 2015 and 2020, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, clinical trial agreements, and other relevant deals. 
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies for Neuromyelitis optica. These were analyzed on the basis of various parameters, such as trial registration year, current trial status, current trial phase, mechanism of action, leading industry and non-industry players with highest number of completed / ongoing trials, regional distribution of clinical trials, and enrolled patient population across different geographies.
  • An insightful analysis on clinical end-points being evaluated in late-stage ongoing and planned studies. For the purpose of this analysis, we considered the phase III clinical studies registered till July 2020, and identified the most important, primary endpoints being evaluated.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population (for the trial in the highest phase of development), route of administration, therapy type and dosing frequency (for quantifying clinical attractiveness), and target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).

The insights presented in this report are backed by a deep understanding of data gathered from secondary sources. The opinions generated over the source of the study, were influenced by inputs from key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to Neuromyelitis optica?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on Neuromyelitis optica is being conducted?
  • Who are the key investors in this domain? 
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Which are the most active clinical trial centres in this domain? 
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?


Table Of Contents




4.1. Neuromyelitis Optica: Marketed and Development Pipeline
4.1.1. Analysis by Type of Molecule
4.1.2. Analysis by Phase of Development
4.1.3. Analysis by Mechanism of Action
4.1.4. Analysis by Route of Administration
4.1.5. Analysis by Dosage Form
4.1.6. Analysis by Target Patient Population

4.2. Neuromyelitis Optica: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Location of Headquarters
4.2.3. Analysis by Geography 





9.1. Neuromyelitis Optica Market: Distribution by Type of Molecule
9.2. Neuromyelitis Optica Market: Distribution by Route of Administration
9.3. Neuromyelitis Optica Market: Distribution by Dosage Form
9.4. Neuromyelitis Optica Market: Distribution by Region






USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases